Aytu BioPharma Inc. (NASDAQ:AYTU – Get Free Report)’s share price passed above its two hundred day moving average during trading on Tuesday after Weiss Ratings upgraded the stock from a sell (d-) rating to a sell (d) rating. The stock has a two hundred day moving average of $2.27 and traded as high as $2.67. Aytu BioPharma shares last traded at $2.66, with a volume of 4,432,223 shares traded.
A number of other research analysts have also recently issued reports on AYTU. Citigroup reissued a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Ascendiant Capital Markets upped their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a report on Thursday, June 11th. Finally, Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Aytu BioPharma currently has a consensus rating of “Hold” and a consensus price target of $8.60.
Check Out Our Latest Research Report on AYTU
Trending Headlines about Aytu BioPharma
- Neutral Sentiment: Maxim Group and Lake Street Capital downgraded AYTU from Buy to Hold; Lake Street’s $2.70 target is in line with the proposed cash offer, leaving the takeover price as a key reference point for investors.
- Negative Sentiment: Coverage of fiscal 2027 first-quarter results said Aytu swung to a loss amid higher costs, which may temper the positive deal news. Aytu BioPharma Swings To Q1 Loss On Higher Costs; Agrees To $56 Mln Buyout By Rosemont
- Negative Sentiment: Several law firms announced investigations into whether the $2.70 offer fairly values Aytu and whether shareholders’ interests were adequately protected. These announcements could add uncertainty around the transaction, though they do not by themselves indicate that the deal will be blocked. Ademi LLP investigates whether buyout fairly values Aytu BioPharma
Institutional Trading of Aytu BioPharma
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nantahala Capital Management LLC purchased a new stake in Aytu BioPharma in the second quarter worth about $2,336,646. Stonepine Capital Management LLC purchased a new position in Aytu BioPharma during the 2nd quarter valued at about $1,962,780. AWM Investment Company Inc. purchased a new position in Aytu BioPharma during the 2nd quarter valued at about $1,332,000. BlackRock Inc. purchased a new position in Aytu BioPharma during the 2nd quarter valued at about $49,000. Finally, Crown Advisors Management Inc. bought a new stake in shares of Aytu BioPharma in the 2nd quarter valued at about $430,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.
Aytu BioPharma Price Performance
The company has a debt-to-equity ratio of 0.26, a current ratio of 1.13 and a quick ratio of 1.00. The firm’s fifty day moving average price is $2.03 and its 200 day moving average price is $2.27.
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.06. The business had revenue of $14.84 million for the quarter, compared to analysts’ expectations of $13.27 million. Aytu BioPharma had a negative return on equity of 74.74% and a negative net margin of 34.34%. Research analysts forecast that Aytu BioPharma Inc. will post -0.16 earnings per share for the current year.
Aytu BioPharma Company Profile
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.
Read More
- Five stocks we like better than Aytu BioPharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
